News
The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the patient's heart.
3d
Medical Device Network on MSNEdwards secures CE mark for transfemoral mitral valve implantEdwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...
The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...
After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...
Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...
Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...
Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...
“nobody calls it TMVI—they call it transcatheter mitral valve replacement. And it’s essentially doing the same thing in that regard.” Francesco Pelliccia, MD (Sapienza University of Rome, Italy), ...
4C Medical Technologies Inc. raised $175 million in a series D financing round led by Boston Scientific Corp. The financing will support the regulatory trials and commercialization of the Altavalve ...
CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of symptomatic tricuspid regurgitation. The procedures will be subject to ...
The US Centers for Medicare & Medicaid Services (CMS) has finalized its national coverage determination (NCD) for transcatheter tricuspid valve replacement (TTVR) when used to treat patients with ...
In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter ... undergoing aortic valve replacement,” the authors wrote.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results